{"entity":{"id":"nct07822542","kind":"trial","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","aka":[],"tldr":"A phase 3 trial of adebrelimab, cisplatin, carboplatin, pemetrexed and other drugs in lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., not yet recruiting.","summary":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07822542 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with a registry enrolment figure of 448 participants, started 2026-10-31 and due to reach its primary completion in 2030-05-31. Interventions recorded: HS-10370; Adebrelimab; Cisplatin; Carboplatin; Pemetrexed; Tislelizumab. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: \"* Interstitial lung disease (ILD)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07822542","url":"https://clinicaltrials.gov/study/NCT07822542"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["kras-g12c-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["adebrelimab","cisplatin","carboplatin","pemetrexed","tislelizumab"],"companies":["hansoh-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07822542","phase":"3","setting":"A Randomized, Open-label, Controlled, Multicenter Phase 3 Trial of HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation.","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","enrolled":448,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07822542/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}